Ocugen to Participate in Upcoming Scientific Conferences
Ocugen will present on its modifier gene therapy platform at Euretina 2026 in Vienna and the American Academy of Ophthalmology Annual Meeting in New Orleans. Presentations cover twelve-month Phase 2 ArMaDa data for OCU410 in geographic atrophy, GARDian1 Phase 1 results for OCU410ST in Stargardt disease, and three-year OCU400 data in retinitis pigmentosa.
Key figures
- Trial phase
- Phase 1/2
- Durable benefit years
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.